rectal cancer
Conditions
Interventions
neoadjuvant chemoradiotherapy
Sponsors
Osaka City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible patients had to have a histologically verified adenocarcinoma of the rectum with the inferior margin within 5cm from the anal verge, as assessed by rectosigmoidoscopy. The tumor had to have evidence of T3/T4 disease or any T disease with positive locoregional lymphnodes detected by computed tomography (CT) and magnetic resonance imaging (MRI) of the pelvis. The disease was considered to be resectable at the time of entry in all cases, with no evidence of distant metastases.
Exclusion criteria
Exclusion criteria: prior radiotherapy, chemotherapy or any molecular targeting therapy for rectal cancer; no other co-existing malignancy or malignancy within the last five years prior to enrollment other than non-melanoma skin cancer or in situ carcinoma of the cervix; no severe concurrent medical or psychiatric illness; no a known hypersensitivity to the study drugs; and none of the patients were pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pCR rate | — |
Secondary
| Measure | Time frame |
|---|---|
| response rate,rate of R0 resection, 3-years survival rate | — |
Countries
Japan
Contacts
Public ContactKiyoshi Maeda
Osaka City University Hospital Department of Surgical Oncology
Outcome results
None listed